For research use only
| Cat No. | ABC-TC0094 |
| Product Type | Human Uterine Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Cervix |
| Disease | Cervical Cancer |
| Product Code | C33A; C33a; C33-A; C-33-A; C-33A; C33 |
C-33 A cell line is a human cervical carcinoma model widely used in HPV-related cancer research, drug screening, and tumor biology investigations.
C-33 A is a human cervical squamous carcinoma cell line originally isolated from the cervix of a 66-year-old Caucasian female patient. These cells exhibit an epithelial, adherent morphology and grow as a uniform monolayer. Cytogenetic analyses show a modal chromosome number of 46, with ~70% of cells exhibiting a pseudodiploid karyotype and occasional polyploid subpopulations. C-33 A harbors a TP53 point mutation at codon 273 (R→C), resulting in elevated mutant p53 protein expression. Additionally, this line is HPV-negative, with no detectable HPV DNA or RNA, making it valuable for studying non-viral cervical carcinogenesis. C-33 A is tumorigenic in vivo, forming undifferentiated carcinomas when xenografted into immunodeficient (nude) mice. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | C33A; C33a; C33-A; C-33-A; C-33A; C33 |
| Species | Human |
| Cat.No | ABC-TC0094 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Cervix |
| Disease | Cervical Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Uterine Cancer Cell Lines |
C-33 A cells are widely used in studies of HPV-independent cervical cancer biology, especially to investigate the role of TP53 mutations in cell cycle regulation, apoptosis, and tumorigenesis. Their unique metabolic profile, including altered lipid and fatty acid metabolism, provides insight into tumor metabolism and identifies potential metabolic vulnerabilities. Additionally, their tumorigenic nature of C-33A in mouse xenografts supports preclinical testing of novel therapies, especially those targeting p53-driven pathways and non-viral oncogenesis.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
